Should Alexion worry about Apellis' Soliris rival? Probably not, analysts say

8th January 2020 Uncategorised 0

With two years to go before biosimilars of its blockbuster Soliris are expected to hit the European market, Alexion is working hard to backstop sales with successor drug Ultomiris. One little complication: A competitor in the wings is touting new Soliris-topping data in an ultra-rare disease, and it could endanger Alexion’s plan.

More: Should Alexion worry about Apellis' Soliris rival? Probably not, analysts say
Source: fierce